None
Quote | Cel-Sci Corporation (NYSE:CVM)
Last: | $1.44 |
---|---|
Change Percent: | 0.0% |
Open: | $1.41 |
Close: | $1.44 |
High: | $1.5201 |
Low: | $1.3875 |
Volume: | 144,157 |
Last Trade Date Time: | 07/23/2024 03:00:00 am |
News | Cel-Sci Corporation (NYSE:CVM)
2024-07-08 09:22:04 ET More on Cel-Sci CEL-SCI gains as FDA greenlights confirmatory study for Multikine Seeking Alpha’s Quant Rating on Cel-Sci Read the full article on Seeking Alpha For further details see: CEL-SCI names Robert Watson as chair
CEL-SCI Corporation (NYSE American: CVM) today announced that Robert (“Bob”) Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. Wi...
Message Board Posts | Cel-Sci Corporation (NYSE:CVM)
Subject | By | Source | When |
---|---|---|---|
So are you no longer in either? Just | renaissance1 | investorshub | 04/30/2023 3:07:58 AM |
Sold my 90k in the $2s last may Cheers | sushifishman | investorshub | 04/29/2023 11:04:41 PM |
Hi Hogg | sushifishman | investorshub | 04/29/2023 10:59:03 PM |
for some reason he's way more triggered about | tarius729 | investorshub | 04/29/2023 9:36:04 PM |
Sushi. Are you still in$ NWBO? They seem | renaissance1 | investorshub | 04/29/2023 3:36:22 AM |
News, Short Squeeze, Breakout and More Instantly...
CEL-SCI Corporation (NYSE American: CVM) today announced that Robert (“Bob”) Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. Wi...
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors 73% survival for Multikine vs 45% in the control arm at 5 years Statistically significant log rank p = 0.0015 ...
Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI’s Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cut...